You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

sintilimab

Showing 1 - 25 of 379
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Safety Issues, Efficacy, MTD Trial in Jilin (Sintilimab 200mg+MB07133 600mg)

Recruiting
  • Safety Issues
  • +2 more
  • Sintilimab 200mg+MB07133 600mg
  • Jilin, Changchun, China
    The First Hospital of Jilin University
Nov 17, 2023

Gastric Cancer Trial in Xi'an (dietary supplement, biological, drug)

Recruiting
  • Gastric Cancer
  • Taurine
  • +4 more
  • Xi'an, Shaanxi, China
    Tang-Du Hospital
Nov 2, 2023

Gastric Cancer, Chemo Effect, Immune Checkpoint Inhibitor Trial in Shanghai (Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU)

Recruiting
  • Gastric Cancer
  • +2 more
  • Sintilimab, paclitaxel-albumin, oxaliplatin, 5-FU
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Aug 1, 2023

Combined Hepatocellular Cholangiocarcinoma Trial (gemcitabine ,oxaliplatin,anlotinib,Sintilimab)

Not yet recruiting
  • Combined Hepatocellular Cholangiocarcinoma
  • gemcitabine ,oxaliplatin,anlotinib,Sintilimab
  • (no location specified)
Sep 10, 2023

Non-squamous Non-small-cell Lung Cancer Trial in Hangzhou (Tusamitamab ravtansine+Sintilimab+Carboplatin or

Not yet recruiting
  • Non-squamous Non-small-cell Lung Cancer
  • Tusamitamab ravtansine+Sintilimab+Carboplatin or Cisplatin+Pemetrexed
  • +2 more
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
May 5, 2023

Gastric Cancer Trial in Shanghai (sintilimab+metronomic PLOF)

Recruiting
  • Gastric Cancer
  • sintilimab+metronomic PLOF
  • Shanghai, China
    Huashan Hospital, Fudan University
Sep 22, 2023

Liver Diseases, Hepatocellular Carcinoma, Immunotherapy Trial in Guangzhou (bTAE-HAIC, Lenvatinib, Sintilimab)

Not yet recruiting
  • Liver Diseases
  • +4 more
  • bTAE-HAIC
  • +2 more
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 30, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • Transarterial Chemoembolization (TACE)
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Solid Tumor Trial in Beijing (XH001+ sintilimab)

Recruiting
  • Solid Tumor
  • XH001+ sintilimab
  • Beijing, Beijing, China
    PLA General Hospital
Jul 10, 2023

Gastric Cancer Trial (Disitamab Vedotin combined with Sintilimab)

Not yet recruiting
  • Gastric Cancer
  • Disitamab Vedotin combined with Sintilimab
  • (no location specified)
Jul 2, 2023

Gastric Cancer Trial (Fruquintinib)

Not yet recruiting
  • Gastric Cancer
  • (no location specified)
Oct 17, 2023

Sintilimab and Anlotinib in Combination With Chemo Trial in Xi'an (Sintilimab and anlotinib in combination with chemo)

Completed
  • Sintilimab and Anlotinib in Combination With Chemotherapy
  • Sintilimab and anlotinib in combination with chemotherapy
  • Xi'an, Shanxi, China
  • +1 more
Aug 27, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, sintilimab plus SIRT)

Not yet recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, sintilimab plus SIRT
  • Guangzhou, Guangdong, China
    The Second Affiliated Hospital of Guangzhou Medical University
Aug 8, 2023

Sintilimab in Combination With Chemoradiotherapy in High-risk

Recruiting
  • Nasopharyngeal Carcinoma
  • Sintilimab
  • Sintilimab (PD-1 Antibody)
  • Nanning, Guangxi, China
    Guangxi Medical University Cancer Hospital
Jan 29, 2023

Advanced Lung Squamous Cell Carcinoma Trial in Chengdu (low-dose radiation therapy and stereotactic body radiation therapy,

Not yet recruiting
  • Advanced Lung Squamous Cell Carcinoma
  • low-dose radiation therapy and stereotactic body radiation therapy
  • +2 more
  • Chengdu, Sichuan, China
    West China Hospital of Sichuan University
Nov 13, 2023

Gastric Cancer Trial in China (Experimental dose: modified XELOX + sintilimab, Standard dose: standard XELOX + sintilimab)

Recruiting
  • Gastric Cancer
  • Experimental dose: modified XELOX + sintilimab
  • Standard dose: standard XELOX + sintilimab
  • Guangzhou, Guangdong, China
  • +9 more
Jun 23, 2023

Esophageal Squamous Cell Carcinoma Trial in Shanghai (Sintilimab, Chemotherapy)

Not yet recruiting
  • Esophageal Squamous Cell Carcinoma
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Nov 30, 2023

Surufatinib Plus Sintilimab Combined With Chemotherapy in

Recruiting
  • Gastric Neuroendocrine Carcinoma
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Institute and Hospital
Oct 22, 2023

Hepatocellular Carcinoma Trial in Hangzhou (Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    Guoliang Shao
Aug 1, 2023

Metastatic Esophageal Squamous Cell Carcinoma Trial in Qingdao (TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1

Recruiting
  • Metastatic Esophageal Squamous Cell Carcinoma
  • TP regimen (cis-platinum ; Tocetaxel ) combined with PD-1 inhibitors（Sintilimab）
  • Qingdao, Shandong, China
  • +1 more
Nov 13, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Sintilimab)

Recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Sep 4, 2023

Hepatocellular Carcinoma Trial in Wuhan (Sintilimab, Lenvatinib, Transarterial Chemoembolization (TACE))

Not yet recruiting
  • Hepatocellular Carcinoma
  • Sintilimab
  • +2 more
  • Wuhan, Hubei, China
    Tongji Hospital, Tongji Medical College, Huazhong University of
Oct 17, 2023

Pancreas Cancer Trial in Jinan (Sintilimab Plus mFFN and Radiation)

Recruiting
  • Pancreas Cancer
  • Sintilimab Plus mFFN and Radiation
  • Jinan, Shandong, China
    Department of Radiation Oncology, Shandong Cancer Hospital and I
Sep 21, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Bevacizumab combined with Sintilimab, Transcatheter arterial chemoembolization)

Recruiting
  • Hepatocellular Carcinoma
  • Bevacizumab combined with Sintilimab
  • Transcatheter arterial chemoembolization
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 14, 2023

Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)

Active, not recruiting
  • Stomach Neoplasms
  • Shanghai, China
    Renji Hospital
Apr 3, 2023